CGEM vs. LENZ, SNDX, SION, XERS, TSHA, ZYME, NUVB, ARDX, AMPH, and TRML
Should you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include LENZ Therapeutics (LENZ), Syndax Pharmaceuticals (SNDX), Sionna Therapeutics (SION), Xeris Biopharma (XERS), Taysha Gene Therapies (TSHA), Zymeworks (ZYME), Nuvation Bio (NUVB), Ardelyx (ARDX), Amphastar Pharmaceuticals (AMPH), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry.
Cullinan Therapeutics vs. Its Competitors
Cullinan Therapeutics (NASDAQ:CGEM) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.
LENZ Therapeutics' return on equity of -25.63% beat Cullinan Therapeutics' return on equity.
In the previous week, Cullinan Therapeutics had 5 more articles in the media than LENZ Therapeutics. MarketBeat recorded 12 mentions for Cullinan Therapeutics and 7 mentions for LENZ Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.49 beat LENZ Therapeutics' score of 0.38 indicating that Cullinan Therapeutics is being referred to more favorably in the media.
LENZ Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cullinan Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 244.83%. LENZ Therapeutics has a consensus price target of $52.80, suggesting a potential upside of 32.10%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than LENZ Therapeutics.
Cullinan Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.
86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 6.9% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
LENZ Therapeutics beats Cullinan Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Cullinan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cullinan Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CGEM) was last updated on 10/14/2025 by MarketBeat.com Staff
